image
Healthcare - Medical - Devices - NYSE - IE
$ 220.12
-0.484 %
$ 21.7 B
Market Cap
36.93
P/E
1. INTRINSIC VALUE

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services.[ Read More ]

The intrinsic value of one STE stock under the base case scenario is HIDDEN Compared to the current market price of 220 USD, STERIS plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STE

image
FINANCIALS
5.14 B REVENUE
3.65%
836 M OPERATING INCOME
211.77%
380 M NET INCOME
259.20%
973 M OPERATING CASH FLOW
28.58%
-887 M INVESTING CASH FLOW
-131.49%
-85.2 M FINANCING CASH FLOW
82.92%
1.33 B REVENUE
3.86%
220 M OPERATING INCOME
-9.21%
157 M NET INCOME
12.23%
251 M OPERATING CASH FLOW
-17.45%
-105 M INVESTING CASH FLOW
-15.32%
-181 M FINANCING CASH FLOW
81.88%
Balance Sheet Decomposition STERIS plc
image
Current Assets 2.87 B
Cash & Short-Term Investments 207 M
Receivables 1.01 B
Other Current Assets 1.65 B
Non-Current Assets 8.19 B
Long-Term Investments 0
PP&E 1.94 B
Other Non-Current Assets 6.26 B
Current Liabilities 931 M
Accounts Payable 252 M
Short-Term Debt 117 M
Other Current Liabilities 562 M
Non-Current Liabilities 3.82 B
Long-Term Debt 3.27 B
Other Non-Current Liabilities 551 M
EFFICIENCY
Earnings Waterfall STERIS plc
image
Revenue 5.14 B
Cost Of Revenue 2.9 B
Gross Profit 2.23 B
Operating Expenses 1.4 B
Operating Income 836 M
Other Expenses 456 M
Net Income 380 M
RATIOS
43.47% GROSS MARGIN
43.47%
16.27% OPERATING MARGIN
16.27%
7.36% NET MARGIN
7.36%
6.00% ROE
6.00%
3.42% ROA
3.42%
6.92% ROIC
6.92%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis STERIS plc
image
Net Income 380 M
Depreciation & Amortization 565 M
Capital Expenditures -360 M
Stock-Based Compensation 56.5 M
Change in Working Capital -146 M
Others 687 M
Free Cash Flow 613 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets STERIS plc
image
Wall Street analysts predict an average 1-year price target for STE of $249 , with forecasts ranging from a low of $225 to a high of $265 .
STE Lowest Price Target Wall Street Target
225 USD 2.22%
STE Average Price Target Wall Street Target
249 USD 13.01%
STE Highest Price Target Wall Street Target
265 USD 20.39%
4. DIVIDEND ANALYSIS
0.23% DIVIDEND YIELD
0.57 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership STERIS plc
image
Sold
0-3 MONTHS
11.5 M USD 1
3-6 MONTHS
2.26 M USD 4
6-9 MONTHS
10.7 M USD 6
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 16, 2024
Sell 2.51 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 10316
243.53 USD
2 months ago
Sep 16, 2024
Sell 852 K USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 3485
244.55 USD
2 months ago
Sep 16, 2024
Sell 1.47 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 5985
245.79 USD
2 months ago
Sep 13, 2024
Sell 774 K USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 3119
248.02 USD
2 months ago
Sep 16, 2024
Sell 106 K USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 427
247.08 USD
2 months ago
Sep 10, 2024
Sell 5.76 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 23332
247 USD
3 months ago
Aug 08, 2024
Sell 113 K USD
HOLLAND CHRISTOPHER S
Director
- 473
239.68 USD
5 months ago
Jun 05, 2024
Sell 1.13 M USD
Majors Cary L
SVP and President, Healthcare
- 4932
229.63 USD
5 months ago
Jun 05, 2024
Sell 748 K USD
Madsen Julia
Senior VP, Life Sciences
- 3252
230 USD
6 months ago
May 16, 2024
Sell 267 K USD
Tamaro Renato
V.P. & Corporate Treasurer
- 1154
231.64 USD
6 months ago
May 15, 2024
Sell 475 K USD
FELDMANN CYNTHIA L
Director
- 2000
237.65 USD
6 months ago
May 15, 2024
Sell 1.18 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 5039
233.34 USD
6 months ago
May 15, 2024
Sell 770 K USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 3281
234.54 USD
6 months ago
May 15, 2024
Sell 4.13 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 17500
235.84 USD
6 months ago
May 15, 2024
Sell 1.46 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 6180
236.22 USD
6 months ago
May 14, 2024
Sell 140 K USD
Sohi Mohsen
Director
- 599
232.96 USD
6 months ago
May 14, 2024
Sell 337 K USD
Sohi Mohsen
Director
- 1438
234.04 USD
6 months ago
May 14, 2024
Sell 708 K USD
Burton Karen L
VP & CAO
- 3000
235.95 USD
6 months ago
May 13, 2024
Sell 1.06 M USD
KOSECOFF JACQUELINE B
Director
- 4584
231.53 USD
6 months ago
May 13, 2024
Sell 470 K USD
Majors Cary L
SVP and President, Healthcare
- 2024
232.13 USD
1 year ago
May 16, 2023
Sell 2.53 M USD
Breeden Richard C
Director
- 12130
208.61 USD
1 year ago
May 16, 2023
Sell 235 K USD
FELDMANN CYNTHIA L
Director
- 1127
208.55 USD
1 year ago
May 16, 2023
Sell 195 K USD
FELDMANN CYNTHIA L
Director
- 931
209.67 USD
1 year ago
May 15, 2023
Sell 439 K USD
Sohi Mohsen
Director
- 2069
212.28 USD
1 year ago
May 15, 2023
Sell 990 K USD
KOSECOFF JACQUELINE B
Director
- 4657
212.56 USD
1 year ago
May 15, 2023
Sell 578 K USD
Breeden Richard C
Director
- 2737
211 USD
1 year ago
Mar 03, 2023
Sell 219 K USD
Majors Cary L
SVP and President, Healthcare
- 1150
190.21 USD
1 year ago
Dec 01, 2022
Sell 308 K USD
Majors Cary L
SVP and President, Healthcare
- 1600
192.51 USD
2 years ago
Jun 15, 2022
Sell 546 K USD
Zangerle John Adam
Sr. VP, Gen Counsel, and Sec.
- 2659
205.31 USD
2 years ago
Apr 20, 2022
Sell 2.04 M USD
Zangerle John Adam
Sr. VP, Gen Counsel, and Sec.
- 8000
255.4845 USD
2 years ago
Apr 07, 2022
Sell 2 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 8000
250 USD
2 years ago
Mar 29, 2022
Sell 984 K USD
Burton Karen L
VP, Controller & CAO
- 4000
246 USD
2 years ago
Feb 15, 2022
Sell 605 K USD
Burton Karen L
VP, Controller & CAO
- 2600
232.61 USD
2 years ago
Feb 10, 2022
Sell 757 K USD
KOSECOFF JACQUELINE B
Director
- 3218
235.2 USD
2 years ago
Feb 10, 2022
Sell 443 K USD
FELDMANN CYNTHIA L
Director
- 1891
234.1 USD
2 years ago
Dec 23, 2021
Sell 7.2 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 30000
240 USD
3 years ago
Nov 15, 2021
Sell 454 K USD
Majors Cary L
Sr VP N America Com Operations
- 1950
232.97 USD
3 years ago
Oct 22, 2021
Sell 4.7 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 20000
235 USD
3 years ago
Aug 26, 2021
Sell 310 K USD
Tamaro Renato
V.P. & Corporate Treasurer
- 1449
213.63 USD
3 years ago
Aug 13, 2021
Sell 2.18 M USD
Majors Cary L
Sr VP N America Com Operations
- 10000
218.43 USD
3 years ago
Aug 13, 2021
Sell 153 K USD
Majors Cary L
Sr VP N America Com Operations
- 701
218.62 USD
3 years ago
Aug 13, 2021
Sell 65.4 K USD
Majors Cary L
Sr VP N America Com Operations
- 299
218.64 USD
3 years ago
May 25, 2021
Sell 361 K USD
FELDMANN CYNTHIA L
Director
- 1890
190.84 USD
3 years ago
May 21, 2021
Sell 601 K USD
KOSECOFF JACQUELINE B
Director
- 3121
192.59 USD
3 years ago
Apr 23, 2021
Sell 215 K USD
Madsen Julia
Senior VP, Life Sciences
- 1000
215 USD
3 years ago
Apr 20, 2021
Sell 210 K USD
Madsen Julia
Senior VP, Life Sciences
- 1000
210 USD
3 years ago
Jan 08, 2021
Sell 202 K USD
Madsen Julia
Senior VP, Life Sciences
- 1000
202 USD
3 years ago
Dec 01, 2020
Sell 302 K USD
LEWIS DAVID B
Director
- 1560
193.79 USD
4 years ago
Nov 09, 2020
Sell 582 K USD
Rosebrough Walter M Jr
President & CEO
- 3014
193.02 USD
4 years ago
Nov 09, 2020
Sell 1.32 M USD
Rosebrough Walter M Jr
President & CEO
- 6786
194.25 USD
4 years ago
Nov 09, 2020
Sell 39 K USD
Rosebrough Walter M Jr
President & CEO
- 200
195.01 USD
4 years ago
Nov 09, 2020
Sell 212 K USD
Madsen Julia
Senior VP, Life Sciences
- 1100
192.36 USD
4 years ago
Nov 09, 2020
Sell 154 K USD
Madsen Julia
Senior VP, Life Sciences
- 800
192.55 USD
4 years ago
Nov 06, 2020
Sell 422 K USD
Rosebrough Walter M Jr
President & CEO
- 2337
180.6 USD
4 years ago
Nov 06, 2020
Sell 1.16 M USD
Rosebrough Walter M Jr
President & CEO
- 6363
181.52 USD
4 years ago
Nov 06, 2020
Sell 237 K USD
Rosebrough Walter M Jr
President & CEO
- 1300
182.19 USD
4 years ago
Nov 05, 2020
Sell 360 K USD
Majors Cary L
Sr VP N America Com Operations
- 2000
180 USD
4 years ago
Nov 05, 2020
Sell 512 K USD
Burton Karen L
VP, Controller & CAO
- 2852
179.38 USD
4 years ago
Nov 05, 2020
Sell 314 K USD
Burton Karen L
VP, Controller & CAO
- 1750
179.48 USD
4 years ago
Oct 09, 2020
Sell 1.12 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 6000
187.17 USD
4 years ago
Oct 09, 2020
Sell 2.95 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 15677
188.24 USD
4 years ago
Oct 08, 2020
Sell 15 K USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 80
187 USD
4 years ago
Oct 09, 2020
Sell 1.18 M USD
TOKICH MICHAEL J
Sr. Vice Pres., CFO
- 6243
189 USD
4 years ago
Oct 06, 2020
Sell 662 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 3664
180.65 USD
4 years ago
Oct 06, 2020
Sell 526 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 2903
181.25 USD
4 years ago
Oct 06, 2020
Sell 630 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 3444
182.86 USD
4 years ago
Oct 06, 2020
Sell 510 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 2777
183.67 USD
4 years ago
Oct 06, 2020
Sell 131 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 712
184.53 USD
4 years ago
Oct 01, 2020
Sell 2.18 M USD
Zangerle John Adam
Sr. VP, Gen Counsel, and Sec.
- 12252
178 USD
4 years ago
Sep 18, 2020
Sell 2.6 M USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 14794
175.51 USD
4 years ago
Sep 18, 2020
Sell 2.6 M USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 14794
175.51 USD
4 years ago
Sep 18, 2020
Sell 36.3 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 206
176.03 USD
4 years ago
Sep 18, 2020
Sell 36.3 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 206
176.03 USD
4 years ago
Sep 15, 2020
Sell 176 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 1039
168.94 USD
4 years ago
Sep 15, 2020
Sell 1.15 M USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 6750
169.66 USD
4 years ago
Sep 15, 2020
Sell 35.9 K USD
Carestio Daniel A
Sr VP and Chief Operating Off
- 211
170.31 USD
4 years ago
Sep 14, 2020
Sell 334 K USD
Zangerle John Adam
Sr. VP, Gen Counsel, and Sec.
- 2000
167 USD
4 years ago
Aug 24, 2020
Sell 3.01 M USD
Breeden Richard C
Director
- 19747
152.45 USD
4 years ago
Aug 24, 2020
Sell 660 K USD
Breeden Richard C
Director
- 4307
153.33 USD
4 years ago
Aug 24, 2020
Sell 146 K USD
Breeden Richard C
Director
- 946
154.32 USD
4 years ago
Aug 25, 2020
Sell 3.01 M USD
Breeden Richard C
Director
- 19494
154.36 USD
4 years ago
Aug 25, 2020
Sell 78.4 K USD
Breeden Richard C
Director
- 506
154.94 USD
4 years ago
Aug 10, 2020
Sell 471 K USD
Majors Cary L
Sr VP N America Com Operations
- 3000
156.8435 USD
4 years ago
Aug 10, 2020
Sell 471 K USD
Majors Cary L
Sr VP N America Com Operations
- 3000
156.8435 USD
4 years ago
Aug 10, 2020
Sell 366 K USD
Majors Cary L
Sr VP N America Com Operations
- 2355
155.62 USD
4 years ago
Aug 10, 2020
Sell 366 K USD
Majors Cary L
Sr VP N America Com Operations
- 2355
155.62 USD
4 years ago
Aug 10, 2020
Sell 34 K USD
Majors Cary L
Sr VP N America Com Operations
- 218
155.88 USD
4 years ago
Aug 10, 2020
Sell 34 K USD
Majors Cary L
Sr VP N America Com Operations
- 218
155.88 USD
4 years ago
Aug 07, 2020
Sell 3.53 M USD
Rosebrough Walter M Jr
President & CEO
- 23066
152.91 USD
4 years ago
Aug 07, 2020
Sell 1.78 M USD
Rosebrough Walter M Jr
President & CEO
- 11552
154.05 USD
4 years ago
Aug 06, 2020
Sell 5.57 M USD
Rosebrough Walter M Jr
President & CEO
- 35867
155.29 USD
4 years ago
Aug 06, 2020
Sell 1.57 M USD
Rosebrough Walter M Jr
President & CEO
- 10131
155.24 USD
4 years ago
Aug 07, 2020
Sell 1.52 M USD
Rosebrough Walter M Jr
President & CEO
- 9799
155.03 USD
4 years ago
Aug 06, 2020
Sell 534 K USD
Rosebrough Walter M Jr
President & CEO
- 3415
156.38 USD
4 years ago
Aug 06, 2020
Sell 2.05 M USD
Rosebrough Walter M Jr
President & CEO
- 13137
155.88 USD
4 years ago
Aug 07, 2020
Sell 915 K USD
Rosebrough Walter M Jr
President & CEO
- 5874
155.79 USD
4 years ago
Aug 06, 2020
Sell 313 K USD
Rosebrough Walter M Jr
President & CEO
- 1996
156.87 USD
4 years ago
Aug 07, 2020
Sell 111 K USD
Rosebrough Walter M Jr
President & CEO
- 709
156.79 USD
4 years ago
Aug 06, 2020
Sell 1.03 M USD
Rosebrough Walter M Jr
President & CEO
- 6539
157.27 USD
4 years ago
May 29, 2020
Sell 438 K USD
Sohi Mohsen
Director
- 2668
164 USD
4 years ago
May 29, 2020
Sell 90.6 K USD
Sohi Mohsen
Director
- 550
164.68 USD
4 years ago
Feb 19, 2020
Sell 6.63 M USD
Rosebrough Walter M Jr
President & CEO
- 39488
168.0028 USD
7. News
Why Steris (STE) International Revenue Trends Deserve Your Attention Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com - 5 days ago
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning. zacks.com - 1 week ago
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Steris (STE) Surpasses Q2 Earnings Estimates Steris (STE) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to earnings of $2.03 per share a year ago. zacks.com - 1 week ago
Steris beats quarterly estimates on continued demand for medical procedures Medical equipment maker Steris beat second-quarter profit estimates on Wednesday, on continued demand for non-urgent medical procedures that boosted sales of its surgical and examination tools. reuters.com - 1 week ago
STERIS Announces Financial Results for Fiscal 2025 Second Quarter DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) --  - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing operations for the second quarter of fiscal 2025 increased 7% to $1.3 billion compared with $1.2 billion in the second quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the second quarter increased 7%. globenewswire.com - 1 week ago
Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. zacks.com - 2 weeks ago
STERIS Declares Dividend of $0.57 per share DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on December 19, 2024, to shareholders of record at the close of business on November 19, 2024. globenewswire.com - 2 weeks ago
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024 DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 second quarter financial results at 9:00 a.m. ET on November 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. globenewswire.com - 3 weeks ago
STE Gears Up for Q2 Earnings: Here's What You Need to Know STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog. zacks.com - 3 weeks ago
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue? Steris (STE) reported earnings 30 days ago. What's next for the stock? zacks.com - 2 months ago
8. Profile Summary

STERIS plc STE

image
COUNTRY IE
INDUSTRY Medical - Devices
MARKET CAP $ 21.7 B
Dividend Yield 0.23%
Description STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Contact 70 Sir John Rogerson's Quay, Dublin, D02 R296 https://www.steris.com
IPO Date June 1, 1992
Employees 18000
Officers Mr. Daniel A. Carestio President, Chief Executive Officer & Director Mr. Andrew Xilas Senior Vice President & GM of Dental Mr. Michael J. Tokich Senior Vice President & Chief Financial Officer Mr. Kenneth E. Kohler Senior Vice President & GM of AST Ms. Mary Clare Fraser SVice President & Chief Human Resources Officer Ms. Julie Winter Vice President of Investor Relations & Corporate Communications Mr. John Adam Zangerle Senior Vice President, General Counsel & Secretary Mr. Cary L. Majors Senior Vice President & President of Healthcare Ms. Karen L. Burton Vice President & Chief Accounting Officer Ms. Julia K. Madsen Senior Vice President & GM of Life Sciences